Pulmonary embolism after dexamethasone treatment for COVID-19: a case report

被引:1
作者
Takahashi, Hidenori [1 ]
Iwasaki, Yoshinobu [1 ]
Watanabe, Takayasu [1 ]
Ichinose, Naoki [2 ]
Oda, Toshimi [2 ]
机构
[1] Showa Gen Hosp, Dept Pulm Med, 8-1-1 Hanakoganei, Kodaira, Tokyo 1878510, Japan
[2] Showa Gen Hosp, Dept Infect Control, Kodaira, Tokyo, Japan
关键词
COVID-19; SARS-CoV-2; Pulmonary embolism; Anticoagulation; Dexamethasone; Cytokine;
D O I
10.1186/s12879-022-07228-2
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background Although the RECOVERY trial showed that dexamethasone was efficacious for the treatment of coronavirus disease 2019 (COVID-19), its impact on the risk of pulmonary embolism (PE) and other serious procoagulant events was not assessed. Case presentation Here we report the case of a previously healthy 83-year-old woman with COVID-19, without any genetic predisposition to thrombosis. She developed moderate respiratory distress 12 days after symptom onset and a 10-day course of dexamethasone therapy was initiated. Her clinical condition and imaging findings improved initially; however, they deteriorated after the completion of dexamethasone therapy, despite the improvement in her pneumonia and viral clearance. Laboratory tests showed markedly raised serum D-dimer, ferritin, and sIL-2R levels, and contrast-enhanced computed tomography showed deep vein thrombosis (DVT) in the left iliac vein and PE of the right pulmonary artery. The DVT and PE were successfully treated using intravenous heparin administration. Conclusions This case illustrates the potential risk of rebound inflammation and procoagulant events following dexamethasone withdrawal. We believe that COVID-19-induced DVT and PE can be affected by dexamethasone therapy. Although dexamethasone reduces procoagulant factors, increases anticoagulant factors, and modulates cytokines, which can suppress/delay thrombus formation during treatment, it confers the risk for rebound cytokine production after treatment completion, triggering cytokine and coagulation cascades that can lead to thromboembolic diseases. In this critical clinical period, the patient's deteriorating condition may be overlooked because of the masking effects of dexamethasone treatment on fever and other clinical conditions and laboratory changes. Clinicians should follow-up coagulation markers carefully and contrast-enhanced computed tomography is useful for detecting coagulation; and, if PE occurs, therapeutic heparin administration is essential because emboli can also generate cytokines.
引用
收藏
页数:5
相关论文
共 19 条
  • [1] Ding J., 2020, NETWORK INFORM ANAL, DOI [10.1101/2020.07.01.20144121, DOI 10.1101/2020.07.01.20144121]
  • [2] Extracellular DNA traps promote thrombosis
    Fuchs, Tobias A.
    Brill, Alexander
    Duerschmied, Daniel
    Schatzberg, Daphne
    Monestier, Marc
    Myers, Daniel D., Jr.
    Wrobleski, Shirley K.
    Wakefield, Thomas W.
    Hartwig, John H.
    Wagner, Denisa D.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (36) : 15880 - 15885
  • [3] The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review
    Gozzo, Lucia
    Viale, Pierluigi
    Longo, Laura
    Vitale, Daniela Cristina
    Drago, Filippo
    [J]. FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [4] Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]
  • [5] Recommendations for the management of hemophagocytic lymphohistiocytosis in adults
    La Rosee, Paul
    Horne, AnnaCarin
    Hines, Melissa
    Greenwood, Tatiana von Bahr
    Machowicz, Rafal
    Berliner, Nancy
    Birndt, Sebastian
    Gil-Herrera, Juana
    Girschikofsky, Michael
    Jordan, Michael B.
    Kumar, Ashish
    van Laar, Jan A. M.
    Lachmann, Gunnar
    Nichols, Kim E.
    Ramanan, Athimalaipet, V
    Wang, Yini
    Wang, Zhao
    Janka, Gritta
    Henter, Jan-Inge
    [J]. BLOOD, 2019, 133 (23) : 2465 - 2477
  • [6] Effects of temperature and humidity on the spread of COVID-19: A systematic review
    Mecenas, Paulo
    da Rosa Moreira Bastos, Renata Travassos
    Rosario Vallinoto, Antonio Carlos
    Normando, David
    [J]. PLOS ONE, 2020, 15 (09):
  • [7] Nishiura H., 2020, CLOSED ENV FACILITAT, DOI [DOI 10.1101/2020.02.28.20029272, 10.1101/2020.02.28.20029272]
  • [8] Antiinflammatory action of glucocorticoids - New mechanisms for old drugs
    Rhen, T
    Cidlowski, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) : 1711 - 1723
  • [9] Diagnosis and Treatment of Pulmonary Embolism During the Coronavirus Disease 2019 Pandemic A Position Paper From the National PERT Consortium
    Rosovsky, Rachel P.
    Grodzin, Charles
    Channick, Richard
    Davis, George A.
    Giri, Jay S.
    Horowitz, James
    Kabrhel, Christopher
    Lookstein, Robert
    Merli, Geno
    Morris, Timothy A.
    Rivera-Lebron, Belinda
    Tapson, Victor
    Todoran, Thomas M.
    Weinberg, Aaron S.
    Rosenfield, Kenneth
    [J]. CHEST, 2020, 158 (06) : 2590 - 2601
  • [10] Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: a narrative review
    Sakr, Yasser
    Giovini, Manuela
    Leone, Marc
    Pizzilli, Giacinto
    Kortgen, Andreas
    Bauer, Michael
    Tonetti, Tommaso
    Duclos, Gary
    Zieleskiewicz, Laurent
    Buschbeck, Samuel
    Ranieri, V. Marco
    Antonucci, Elio
    [J]. ANNALS OF INTENSIVE CARE, 2020, 10 (01)